文献速递造血干细胞移植与细胞治疗

COVID-19大流行初期异基因造血细胞移植物冷冻保存的临床影响

Clinical impact of cryopreservation of allogeneic hematopoietic cell grafts during the onset of the COVID-19 pandemic.
PubMed 文献 · Blood Adv · 2023-01-01

研究基于国际血液与骨髓移植研究中心数据库,比较大流行前6个月1543例接受冷冻保存异基因移植物的受者与2019年6个月期间2499例接受新鲜移植物的受者。多变量回归分析显示两组总生存无差异(P=0.09),但冷冻保存组无病生存较低(P=0.006)、复发风险较高(P=0.01)、原发植入失败较高(P=0.01)、慢性移植物抗宿主病风险较低(P=0.001)。结论认为冷冻保存对总生存无负面影响,但复发较高、无病生存较低;随着大流行相关后勤障碍解决,推荐使用新鲜移植物,新鲜移植物不可行时可考虑冷冻保存。

要点

  • 冷冻保存组与新鲜移植物组总生存无差异(P=0.09)。
  • 冷冻保存组无病生存较低(P=0.006),复发风险较高(P=0.01)。
  • 冷冻保存组原发植入失败较高(P=0.01),慢性GVHD风险较低(P=0.001)。

核心结论

  • 冷冻保存对总生存无负面影响,但复发较高、无病生存较低;随着大流行相关后勤障碍解决,推荐使用新鲜移植物,新鲜移植物不可行时可考虑冷冻保存。

研究设计与样本

  • 利用国际血液与骨髓移植研究中心结局数据库,分析大流行前6个月在美国中心接受冷冻保存异基因移植的1543例受者,并与2019年6个月期间接受新鲜异基因移植的2499例受者比较。

主要发现

  • 多变量回归分析显示冷冻保存组与新鲜移植物组总生存无差异(P=0.09)。
  • 非复发死亡无差异(P=0.89),移植物抗宿主病无差异,无GVHD和无复发生存无差异(P=0.58)。
  • 冷冻保存组无病生存较低(P=0.006),复发风险较高(P=0.01)。
  • 冷冻保存组原发植入失败较高(P=0.01),慢性GVHD风险较低(P=0.001)。

临床怎么用

  • 随着大流行相关后勤障碍解决,推荐使用新鲜移植物。
  • 新鲜移植物不可行时,可考虑冷冻保存作为患者的选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

At the onset of the COVID-19 pandemic, the National Marrow Donor Program mandated the cryopreservation of hematopoietic cell grafts from volunteer unrelated donors because of numerous patient and donor safety concerns and logistical hurdles. Using the Center for International Blood and Marrow Transplant Research outcomes database, we report the impact of cryopreservation on overall survival (OS) and other outcomes within 1 year after hematopoietic cell transplantation (HCT). We analyzed 1543 recipients of cryopreserved allografts receiving HCT at US centers during the first 6 months of the pandemic and compared them with 2499 recipients of fresh allografts during a 6-month period in 2019. On multivariable regression analysis, we observed no difference in the OS (P = .09), nonrelapse mortality (P = .89), graft-versus-host disease (GVHD), or GVHD- and relapse-free survival (P = .58) in recipients of cryopreserved vs fresh allografts. Disease-free survival (DFS) was lower in the cryopreserved allograft recipients (P = .006) because of a higher risk of relapse (P = .01) compared with the fresh allograft recipients. Primary graft failure was higher (P = .01), and the risk of chronic GVHD was lower (P = .001) with cryopreservation compared with fresh grafts. In conclusion, although there was no negative impact of cryopreservation on OS, relapse was higher, and DFS was lower than that with no cryopreservation. Fresh grafts are recommended as the pandemic-related logistical hurdles resolve. Cryopreservation should be considered an option for patients when fresh grafts are not feasible.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Devine SM, Bo-Subait S, Kuxhausen M, et al. Clinical impact of cryopreservation of allogeneic hematopoietic cell grafts during the onset of the COVID-19 pandemic. Blood Adv. 2023. PMID: 37036959. doi:10.1182/bloodadvances.2023009786

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。